GlassScriptPhysician profile
August S Olinger
NPI 1396144523
$2,603.52
in general payments reported to CMS, 2019-2025
34 companies · $442 in 2025
The $442 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,261 · 2022: $242 · 2023: $176 · 2024: $482 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,100.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $238.43 | 2024-2025 | Korlym |
| Abbvie INC. | $235.33 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $209.55 | 2021-2024 | Xarelto |
| Amgen INC. | $204.09 | 2021-2025 | Repatha, Otezla, Prolia |
| Novo Nordisk INC | $199.70 | 2021-2025 | Ozempic, Rybelsus |
| Inspire Medical Systems, INC. | $142.61 | 2023-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $139.75 | 2021-2025 | Breztri |
| Lilly USA, LLC | $134.28 | 2021-2025 | Zepbound, Jardiance, Mounjaro |
| Esperion Therapeutics, INC. | $118.96 | 2021 | |
| Pfizer INC. | $109.60 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $99.53 | 2021-2025 | |
| Dexcom, INC. | $95.37 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.39 | 2021-2024 | Jardiance |
| Glaxosmithkline, LLC. | $78.77 | 2021-2025 | Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $48.33 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $41.81 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.74 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.41 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $34.51 | 2024 | |
| Merck Sharp & Dohme LLC | $30.87 | 2021-2024 | Capvaxive |
| Biogen, INC. | $28.75 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.50 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $27.17 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $26.56 | 2021 | |
| Amarin Pharma, INC. | $19.48 | 2021 | |
| Exact Sciences Corporation | $19.37 | 2025 | The Cologuard Plus Collection Kit |
| Abbott Laboratories | $17.28 | 2024 | Freestyle Libre 3 |
| Recordati_rare_diseases_inc. | $17.06 | 2025 | Isturisa |
| Alkermes, INC. | $16.34 | 2023 | Vivitrol |
| Kci USA, INC. | $15.70 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.58 | 2021 | |
| Vifor Pharma, INC. | $15.45 | 2021 | |
| Sumitomo Pharma America, INC. | $14.72 | 2025 | Gemtesa |
| Lundbeck LLC | $14.53 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw August Olinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.